IL2 and neoplasm: Concerning IL-2 immunocytokines combined with anti-angiogenic treatments, the critical role of the cell surface heparan sulfate proteoglycan syndecan-1 (SDC1, CD138) in neovascularization, vasculogenic mimicry (VM), and tumor progression is well established.